YolTech Therapeutics Secures $45 Million for Gene-Editing Advances

Author: Thomas Cooper Updated: 09-11-2025 08:09 AM

YolTech Therapeutics Achieves Major Funding Milestone

YolTech Therapeutics, a pioneering force in in vivo genome editing therapies, has announced a successful Series B financing round, raising approximately $45 million. This funding was prominently led by the AstraZeneca-CICC healthcare investment fund, marking a significant milestone in the company’s journey.

Advancing Innovative Therapeutic Solutions

Dr. Yuxuan Wu, the Founder and CEO of YolTech, expressed enthusiasm, stating that this financing is a pivotal moment as the company progresses with its clinical pipeline. The funds will be utilized to push forward their cutting-edge gene-editing programs. YolTech is committed to transforming the latest advances in gene editing into real-world therapies that can provide meaningful benefits to patients globally.

About YolTech Therapeutics

Founded in 2021, YolTech Therapeutics specializes in developing next-generation in vivo gene-editing therapies intended for one-time administration. The company has established a robust platform that includes proprietary CRISPR nucleases known as YolCas, innovative base editors named YolBE, and an advanced lipid nanoparticle delivery system referred to as Yol-LNPs. This unique combination allows for accurate, efficient, and tissue-specific gene editing across a wide variety of therapeutic areas.

Significant Milestones in Clinical Research

In a remarkable achievement, YolTech's lead program YOLT-201, a CRISPR-based therapy addressing transthyretin amyloidosis (ATTR), became the first in vivo gene-editing therapy in the region to begin Phase I/IIa clinical trials. Since this initial clinical trial, the company has further advanced four additional clinical-stage programs targeting conditions such as ATTR, familial hypercholesterolemia (HeFH), primary hyperoxaluria type 1 (PH1), and ?-thalassemia/sickle cell disease (TDT/SCD).

Ensuring Quality Manufacturing

YolTech proudly operates a cGMP-compliant manufacturing facility that supports clinical supply through to Phase III and early commercial scaling. This commitment to quality guarantees manufacturing consistency and scalability, which are critical elements in the company’s ongoing programs.

Leadership in the Gene-Editing Field

With one of the most comprehensive in vivo gene-editing clinical pipelines on a global scale, YolTech is consistently at the forefront of innovation in the field. The company’s base-editing therapy YOLT-101, designed for familial hypercholesterolemia (HeFH), notably became the first in vivo base-editing program to secure IND clearance in both China and the United States.

Frequently Asked Questions

What is the purpose of YolTech Therapeutics?

YolTech Therapeutics focuses on developing innovative in vivo gene-editing therapies to create effective, one-time treatments for various genetic diseases.

How much funding did YolTech recently secure?

YolTech Therapeutics successfully raised approximately $45 million in its Series B financing round.

Who led the recent funding for YolTech?

The funding round was led by the AstraZeneca-CICC healthcare investment fund.

What are the key therapies being developed by YolTech?

YolTech is working on therapies targeting transthyretin amyloidosis (ATTR), familial hypercholesterolemia (HeFH), primary hyperoxaluria type 1 (PH1), and ?-thalassemia/sickle cell disease (TDT/SCD).

When was YolTech founded?

YolTech Therapeutics was founded in 2021, positioning itself as a leader in the gene-editing space.

About The Author

Hello, I'm Thomas Cooper, a financial expert and writer passionate about helping people understand and navigate the financial world. Having a solid financial background and a lot of experience, my area of expertise is simplifying difficult financial ideas into useful, understandable guidance. My goal with my writings and blog entries is to provide you the information and resources you need to make wise financial choices.

I am thrilled to contribute my ideas and engage with a lively investor community at Investors Hangout, where I recently joined the team. My mission is to make finance interesting and approachable so you may take charge of your financial future. I appreciate you coming along on this path to success and financial knowledge.

Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.